Immune infiltrating cells in duodenal cancers.
Duodenal cancer
Prognosis
Tumor infiltrating cells
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
03 09 2020
03 09 2020
Historique:
received:
19
03
2020
accepted:
26
08
2020
entrez:
5
9
2020
pubmed:
5
9
2020
medline:
15
5
2021
Statut:
epublish
Résumé
Duodenal adenocarcinoma (DA) is a rare yet aggressive malignancy, with increasing incidence in the last decades. Its low frequency has hampered a thorough understanding of the pathogenesis of the disease and of its biology, limiting the identification of tailored therapeutic options. A large body of evidence has clearly shown the clinical relevance of immune cells in solid tumors, correlating immune features with post-surgical prognosis. The aim of this study was to analyze the immune contexture in a cohort of duodenal adenocarcinomas surgically resected at our Institution and define its correlation with clinical variables. Tissue slides from paraffin-embedded tumor specimens of 15 consecutive DA and 3 adenomas that underwent a pancreaticoduodenectomy in our center between 2010 to 2018 were immunohistochemically stained. The density (percentage of immune reactive area, IRA%) of immune markers CD45RO, CD8, CD20, IL-17, PD-1, CD68 was quantified by computer-assisted image analysis. Demographic, clinical, histopathological data were collected. In our population, median IRA % (IQR) of immune subsets was respectively CD45RO-TILs 2.19 (2.14), CD8-TIL 0.42 (0.81), CD20-TILs 0.22 (0.51), CD20-TLT 2.84 (4.64), CD68-TAM 2.19 (1.56), IL17 Immune cells showed variable expression in correlation with common prognostic factors, suggesting T cell infiltration may play a protective role towards lymphatic spread of disease and nodal metastatization. Furthermore, T cell density and macrophage infiltration were associated to a lower risk of recurrence and disease related death. A multicentric approach may be indicated to allow analysis of larger cohorts of patients, potentially increasing the power of our observations.
Sections du résumé
BACKGROUND
Duodenal adenocarcinoma (DA) is a rare yet aggressive malignancy, with increasing incidence in the last decades. Its low frequency has hampered a thorough understanding of the pathogenesis of the disease and of its biology, limiting the identification of tailored therapeutic options. A large body of evidence has clearly shown the clinical relevance of immune cells in solid tumors, correlating immune features with post-surgical prognosis. The aim of this study was to analyze the immune contexture in a cohort of duodenal adenocarcinomas surgically resected at our Institution and define its correlation with clinical variables.
METHODS
Tissue slides from paraffin-embedded tumor specimens of 15 consecutive DA and 3 adenomas that underwent a pancreaticoduodenectomy in our center between 2010 to 2018 were immunohistochemically stained. The density (percentage of immune reactive area, IRA%) of immune markers CD45RO, CD8, CD20, IL-17, PD-1, CD68 was quantified by computer-assisted image analysis. Demographic, clinical, histopathological data were collected.
RESULTS
In our population, median IRA % (IQR) of immune subsets was respectively CD45RO-TILs 2.19 (2.14), CD8-TIL 0.42 (0.81), CD20-TILs 0.22 (0.51), CD20-TLT 2.84 (4.64), CD68-TAM 2.19 (1.56), IL17
CONCLUSIONS
Immune cells showed variable expression in correlation with common prognostic factors, suggesting T cell infiltration may play a protective role towards lymphatic spread of disease and nodal metastatization. Furthermore, T cell density and macrophage infiltration were associated to a lower risk of recurrence and disease related death. A multicentric approach may be indicated to allow analysis of larger cohorts of patients, potentially increasing the power of our observations.
Identifiants
pubmed: 32883314
doi: 10.1186/s12967-020-02508-4
pii: 10.1186/s12967-020-02508-4
pmc: PMC7470614
doi:
Substances chimiques
Biomarkers
0
Leukocyte Common Antigens
EC 3.1.3.48
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
340Références
Nat Rev Clin Oncol. 2013 Sep;10(9):534-44
pubmed: 23897080
Mod Pathol. 2018 Feb;31(2):214-234
pubmed: 29192647
Exp Mol Med. 2018 Dec 13;50(12):1-11
pubmed: 30546008
Am J Surg. 2010 Jun;199(6):797-803
pubmed: 20609724
Cancer. 2004 Aug 1;101(3):518-26
pubmed: 15274064
Blood. 2003 Apr 1;101(7):2620-7
pubmed: 12411307
Am J Gastroenterol. 1992 Jan;87(1):37-42
pubmed: 1728122
World J Gastrointest Surg. 2016 Mar 27;8(3):212-21
pubmed: 27022448
Curr Opin Immunol. 2013 Apr;25(2):261-7
pubmed: 23579076
Oncoimmunology. 2015 Sep 11;5(4):e1085147
pubmed: 27141376
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Ann Surg. 2009 Jan;249(1):63-71
pubmed: 19106677
Kaohsiung J Med Sci. 2014 May;30(5):254-9
pubmed: 24751389
Lancet Oncol. 2009 Sep;10(9):877-84
pubmed: 19656725
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Oncoimmunology. 2017 Jul 12;6(12):e1342918
pubmed: 29209561
Gut. 2017 Apr;66(4):692-704
pubmed: 26719303
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Langenbecks Arch Surg. 2019 Jun;404(4):439-449
pubmed: 30972486
Clin Cancer Res. 2014 Apr 15;20(8):2147-58
pubmed: 24523438
Immunity. 2014 Dec 18;41(6):1052-63
pubmed: 25526314
Clin Cancer Res. 2007 Mar 1;13(5):1472-9
pubmed: 17332291
Ann Surg Oncol. 2012 May;19(5):1439-45
pubmed: 22187121
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Gut. 2016 Oct;65(10):1710-20
pubmed: 26156960
Immunity. 2013 Jul 25;39(1):11-26
pubmed: 23890060
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Cancer Res. 2013 Jan 1;73(1):128-38
pubmed: 23135914
Cancer. 2010 Dec 1;116(23):5374-82
pubmed: 20715162
Oncogene. 2010 Feb 25;29(8):1093-102
pubmed: 19946335
Cancer Res. 2011 Sep 1;71(17):5601-5
pubmed: 21846822